DK1140139T4 - Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier - Google Patents

Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier

Info

Publication number
DK1140139T4
DK1140139T4 DK99966958T DK99966958T DK1140139T4 DK 1140139 T4 DK1140139 T4 DK 1140139T4 DK 99966958 T DK99966958 T DK 99966958T DK 99966958 T DK99966958 T DK 99966958T DK 1140139 T4 DK1140139 T4 DK 1140139T4
Authority
DK
Denmark
Prior art keywords
erythropoietin
cerebral
treatment
ischaemia
derivatives
Prior art date
Application number
DK99966958T
Other languages
English (en)
Other versions
DK1140139T3 (da
Inventor
Hannelore Ehrenreich
Christoph Gleiter
Original Assignee
Christoph Gleiter
Hannelore Ehrenreich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1140139(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Christoph Gleiter, Hannelore Ehrenreich filed Critical Christoph Gleiter
Publication of DK1140139T3 publication Critical patent/DK1140139T3/da
Application granted granted Critical
Publication of DK1140139T4 publication Critical patent/DK1140139T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK99966958T 1998-12-14 1999-12-13 Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier DK1140139T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PCT/EP1999/009864 WO2000035475A2 (de) 1998-12-14 1999-12-13 Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Publications (2)

Publication Number Publication Date
DK1140139T3 DK1140139T3 (da) 2004-03-15
DK1140139T4 true DK1140139T4 (da) 2009-06-08

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99966958T DK1140139T4 (da) 1998-12-14 1999-12-13 Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier

Country Status (26)

Country Link
US (1) US7514072B1 (da)
EP (1) EP1140139B2 (da)
JP (2) JP4750947B2 (da)
KR (1) KR100774827B1 (da)
CN (1) CN1187085C (da)
AT (1) ATE253932T1 (da)
AU (1) AU766216C (da)
BG (1) BG65417B1 (da)
BR (1) BR9916197A (da)
CA (1) CA2353553C (da)
DE (2) DE19857609A1 (da)
DK (1) DK1140139T4 (da)
ES (1) ES2211218T5 (da)
HK (1) HK1042655B (da)
HU (1) HUP0104709A3 (da)
ID (1) ID29107A (da)
IL (2) IL143579A0 (da)
MX (1) MXPA01005971A (da)
NO (1) NO330079B1 (da)
NZ (1) NZ541591A (da)
PL (1) PL202483B1 (da)
PT (1) PT1140139E (da)
RO (1) RO121409B1 (da)
RU (1) RU2242991C2 (da)
WO (1) WO2000035475A2 (da)
ZA (1) ZA200104626B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
AU784550B2 (en) * 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2002325712C1 (en) 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
JP4906231B2 (ja) 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
NZ542092A (en) * 2003-03-27 2008-04-30 Janssen Pharmaceutica Nv Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
BRPI0414887A (pt) 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US7534765B2 (en) * 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
KR20080103108A (ko) 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
AR061269A1 (es) * 2006-06-07 2008-08-13 Chugai Pharmaceutical Co Ltd Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP3537151B2 (ja) * 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
HUT73876A (en) 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU784550B2 (en) 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
EP1140139A2 (de) 2001-10-10
ATE253932T1 (de) 2003-11-15
ES2211218T3 (es) 2004-07-01
AU766216C (en) 2004-11-11
WO2000035475A2 (de) 2000-06-22
IL143579A0 (en) 2002-04-21
JP4750947B2 (ja) 2011-08-17
AU766216B2 (en) 2003-10-09
DE19857609A1 (de) 2000-06-15
JP2011079860A (ja) 2011-04-21
WO2000035475A3 (de) 2000-10-19
CA2353553C (en) 2011-05-17
HUP0104709A3 (en) 2002-05-28
JP2002532432A (ja) 2002-10-02
BR9916197A (pt) 2001-09-04
RO121409B1 (ro) 2007-05-30
RU2242991C2 (ru) 2004-12-27
AU2283100A (en) 2000-07-03
BG65417B1 (bg) 2008-07-31
CA2353553A1 (en) 2000-06-22
BG105575A (en) 2002-01-31
NO330079B1 (no) 2011-02-14
NZ541591A (en) 2007-08-31
ID29107A (id) 2001-07-26
DK1140139T3 (da) 2004-03-15
EP1140139B1 (de) 2003-11-12
EP1140139B9 (de) 2004-03-31
HK1042655A1 (en) 2002-08-23
KR100774827B1 (ko) 2007-11-07
HUP0104709A2 (hu) 2002-04-29
PL349335A1 (en) 2002-07-15
NO20012896D0 (no) 2001-06-12
ES2211218T5 (es) 2009-06-03
CN1187085C (zh) 2005-02-02
CN1335776A (zh) 2002-02-13
ZA200104626B (en) 2002-09-06
US7514072B1 (en) 2009-04-07
PL202483B1 (pl) 2009-06-30
MXPA01005971A (es) 2002-03-27
HK1042655B (zh) 2005-09-23
DE59907752D1 (de) 2003-12-18
PT1140139E (pt) 2004-04-30
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
NO20012896L (no) 2001-08-14
KR20010082346A (ko) 2001-08-29

Similar Documents

Publication Publication Date Title
DK1140139T4 (da) Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier
EP4442241A3 (en) Retinol replacement in skin treatment
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
ATE200422T1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
NO975192D0 (no) Bicykliske aromatiske forbindelser
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2007046097A3 (en) Topical compositions for the treatment of depilation-induced skin irritation or prevention thereof
ATE141045T1 (de) Schlankmachende zusammensetzung
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
FR2746098B1 (fr) Composes propynyl biaromatiques
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
EA199800589A1 (ru) Применение экстрактов гинкго двудольного для получения фармацевтичиских композиций и способ косметической обработки с его использованием
KR102163775B9 (ko) 7-벤질-4-7H-피롤로[2,3-d]피리미딘 유도체 및 이를 유효성분으로 함유하는 피부 미백용 조성물 및 멜라닌 색소 과다 침착 질환의 예방 또는 치료용 약학적 조성물
DE60003074D1 (de) Fusidinsäure-derivate
NO20021241L (no) Farmasöytiske og/eller kosmetiske blandinger
IS2392B (is) Sítalópram til að meðhöndla hækkaðan blóðþrýsting
ATE406888T1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
TW200508229A (en) Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
IT1310326B1 (it) Pomata per la cura delle lesioni cutanee particolarmente delle ustioni
BR0214644A (pt) Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação
BR9909530A (pt) Tratamento de doenças parasitárias pela inibição das proteases de cisteìna da superfamìlia da papaìna